Compare Travere Therapeutics Inc. Common Stock (TVTX) vs XPO Inc. Common Stock (XPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs XPO Inc. Common Stock — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while XPO Inc. Common Stock trades at $187.74 (market cap $21.21B). The key difference: XPO Inc. Common Stock is far larger — about 4.3× Travere Therapeutics Inc. Common Stock's market cap, and XPO Inc. Common Stock is more actively traded (663,957 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and XPO Inc. Common Stock for 6 Days on average.
| TVTX | XPO | |
|---|---|---|
Market Cap | $4.88B | $21.21B |
Volume | 1,668,577 | 663,957 |
Sector | Health | Industrials |
52-Week High | $67.52 | $228.37 |
52-Week Low | $26.79 | $123.66 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $5.01B | $24.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XPO trades at $181.15, up 0.35% today, with a bearish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $8.6B in 2026, and net income margin improved to 4.71%. Recent news highlights operational expansions and industry recognition, such as new service centers and a FreightTech 100 award.
The outlook is positive with strong analyst support—71.9% recommend Buy and a consensus price target of $227.64 implies ~26% upside. Key risks include high valuation multiples (P/E 53.44) and exposure to freight market volatility. Earnings growth and margin improvements are primary catalysts, but investors should monitor competitive pressures and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About XPO Inc. Common Stock
XPO provides freight transportation services in North America and Europe. Its operations include less-than-truckload freight transportation and brokerage services supported by a technology platform.
Read more on XPO →
